1 Schnirer, II, Yao JC, Ajani JA. Carcinoid – a comprehensive review. Acta oncologica (Stockholm, Sweden). 2003;42:672–92.
2 Grozinsky-Glasberg S, Grossman AB, Gross DJ. Carcinoid Heart Disease: From Pathophysiology to Treatment – «Something in the Way It Moves». Neuroendocrinology. 2015;101:263–73.
3 Meijer WG, Kema IP, Volmer M, Willemse PH, de Vries EG. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clinical chemistry. 2000;46:1588–96.
4 Michael J. Raphael MD DLCM, Calvin Law MD, Simron Singh MD. Principles of diagnosis and management of neuroendocrine tumours. CMAJ. 2017;189.
5 Maggard MA, O’Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Annals of surgery. 2004;240:117–22.
6 Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999;17:1111.
7 Kulke MH, Horsch D, Caplin ME, Anthony LB, Bergsland E, Oberg K, et al. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Journal of clinical oncology. 2017;35:14–23.